Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer. - Wikidata - awgldk - TriplyDB

Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer.

Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer.

http://www.wikidata.org/entity/Q35012858

about

Clinical significance of increased expression of Nijmegen breakage syndrome gene (NBS1) in human primary liver cancer Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature.Risk factors of locoregional relapse in locally advanced breast cancer treated with neoadjuvant chemotherapy following mastectomy and radiotherapy.Correlation of IDH1 mutation with clinicopathologic factors and prognosis in primary glioblastoma: a report of 118 patients from China An integrated microfluidic cell array for apoptosis and proliferation analysis induction of breast cancer cells Use of the comet-FISH assay to compare DNA damage and repair in p53 and hTERT genes following ionizing radiation Endometrial Endometrioid Carcinoma Metastases Show Decreased ER-Alpha and PR-A Expression Compared to Matched Primary Tumors.Macroscopic optical physiological parameters correlate with microscopic proliferation and vessel area breast cancer signatures.Comparison of the expression of prognostic biomarkers between primary tumor and axillary lymph node metastases in breast cancer.Molecular response to aromatase inhibitor treatment in primary breast cancer.Predicting Responses to Neoadjuvant Chemotherapy in Breast Cancer: ACRIN 6691 Trial of Diffuse Optical Spectroscopic Imaging Histological grading of breast cancer on needle core biopsy: the role of immunohistochemical assessment of proliferation.Factors that predict early treatment failure for patients with locally advanced (T4) breast cancer.Retrospective analysis of 119 Chinese noninflammatory locally advanced breast cancer cases treated with intravenous combination of vinorelbine and epirubicin as a neoadjuvant chemotherapy: a median follow-up of 63.4 months.The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression-Based Meta-Analysis.Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity.Predictive biomarkers in breast cancer: their value in neoadjuvant chemotherapy.Macroscopic handling and reporting of breast cancer specimens pre- and post-neoadjuvant chemotherapy treatment: review of pathological issues and suggested approaches.Treatment response to preoperative anthracycline-based chemotherapy in locally advanced breast cancer: the relevance of proliferation and apoptosis rates.Glutamine depletion by crisantaspase hinders the growth of human hepatocellular carcinoma xenografts.Apigenin induces apoptosis and blocks growth of medroxyprogesterone acetate-dependent BT-474 xenograft tumors.The search for optimal cutoff points for apoptosis and proliferation rate in prognostification of early stage breast cancer patients treated with anthracyclines in adjuvant settings.Prognostic factors of survival in pathologic incomplete response patients with locally advanced breast cancer after neoadjuvant chemotherapy.Analysis of radiation-induced cell death in head and neck squamous cell carcinoma and rat liver maintained in microfluidic devices.Survival outcome and reduction rate of Ki-67 between pre- and post-neoadjuvant chemotherapy in breast cancer patients with non-pCR.FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.Biomedical application of fuzzy association rules for identifying breast cancer biomarkers.Ki-67 Expression by Immunohistochemistry and Quantitative Real-Time Polymerase Chain Reaction as Predictor of Clinical Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.Ki67 Changes Identify Worse Outcomes in Residual Breast Cancer Tumors After Neoadjuvant Chemotherapy.Impact of biomarker changes during neoadjuvant chemotherapy for clinical response in patients with residual breast cancers.Endocrine Resistance in Breast Cancer

P2860

Q28265438-46D8FC1F-EC0A-40FB-B63E-2180EB64E12C Q30854643-77704098-67B0-401A-8259-4D94ADDAEC88 Q33889349-C3FAF155-2BA3-4C02-A320-F82F29AEED54 Q34146009-2ED6C0A4-187B-4DA6-A1C5-4D4E39D68BB5 Q34252992-0EA28311-8E4D-4B6D-BF06-45C6018D6174 Q34474457-0DEE187D-8A93-4CEC-B87E-49FE9316C347 Q35739831-90EDE5ED-3B36-4D00-8AAF-5D4E38950C11 Q35806203-E65FB63A-E213-4993-823A-119BB2445EA5 Q35854369-8951E31A-B642-4D30-A443-8409A392110E Q35906338-F8734E06-7FA1-4242-B042-61E7291D3E9B Q36104503-28069ACF-482A-4C70-BAD7-528BB75DA67C Q36587555-551547B4-1C76-4495-AAAD-8816AADBABA5 Q36696517-9AF7CA24-78A6-4EBD-BF25-4A673EA288A6 Q37405890-F79C61A8-E12D-4D88-AACA-B50EA027E012 Q37510518-519BC3CD-A6C5-4656-971F-909C821970AE Q37592617-C36F764D-735B-4591-9E6C-40F111E2E199 Q38047337-40B35B82-9770-473B-AA1E-07CA423C8067 Q38317182-019D87CA-4231-4A65-8377-82AF165021FB Q38397572-80E7D2E7-3953-42EC-B3D1-2383087A6F46 Q38970692-58DD7B6D-9898-4DD4-A9B2-1E6B02E8AF18 Q39351791-D9A4DDCB-AA2A-4E92-A7EA-814F35018DD9 Q41034390-9F44A11C-C5AF-4FBC-AC7D-BEB99328CDFC Q43522921-91F6CDEB-1D63-4667-B801-B06455301EC1 Q44847130-01F835DB-D995-483F-9DB4-6D339C4FCC7E Q45173811-307E362E-5567-4AA0-840D-AFB17594A1AD Q45212093-58409BE3-559A-45CB-ABD0-B4A33FAE915F Q46736635-A8432FA6-FF9B-4F99-8A52-61FB032A3701 Q47160829-C4BB1D90-0701-45F5-86F8-16D620604FA1 Q51018339-9CE649DB-B090-420F-821F-BFD7759711F4 Q52680900-1F9992FB-0E13-49C2-B22B-D847D288871E Q53674063-B83EC056-16E2-4A39-AA2B-29FD6D91232E Q59072640-3EA03084-4447-43B1-A295-749C9585F510

P2860

Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer.

http://www.wikidata.org/entity/Q35012858

description

2006 nî lūn-bûn

@nan

2006 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Evaluation of Ki-67 proliferat ...... apy for primary breast cancer.

@ast

Evaluation of Ki-67 proliferat ...... apy for primary breast cancer.

@en

type

label

Evaluation of Ki-67 proliferat ...... apy for primary breast cancer.

@ast

Evaluation of Ki-67 proliferat ...... apy for primary breast cancer.

@en

prefLabel

Evaluation of Ki-67 proliferat ...... apy for primary breast cancer.

@ast

Evaluation of Ki-67 proliferat ...... apy for primary breast cancer.

@en

P1433

Q35012858-526847C5-6004-4821-9498-C9A28EC653B7

P1476

Q35012858-AA63C8CB-7532-433D-83DA-838D018B4BB3

P2093

Q35012858-33722AD1-0E50-41B4-AFCA-05331798C746

Q35012858-3CC3D771-299C-4B8C-A223-5C06E7DB945B

Q35012858-6299BDBC-8187-4ADD-8E66-B8802C4A3C8E

Q35012858-6EE8EF02-C23B-4D52-B09F-B936E8BA3A61

Q35012858-A41E008E-2A40-4DEA-B67E-18E6A21657B6

Q35012858-AF5E2ACC-0C00-42DA-992B-13126D9BAC3B

Q35012858-E2BB547B-B221-4311-8F2E-08E9274F72A2

P2860

Q35012858-14EE5A60-A8DB-4FF5-90DD-018F783D8527

Q35012858-1523A356-F4EA-42E8-BEE1-8A03FA9F8076

Q35012858-1C69FA07-E334-4E3A-BAFD-8C1DBAD9B368

Q35012858-2510EEFB-D025-4811-A118-E8F5EB5BAB88

Q35012858-3A16D6F9-4EC1-43A3-A290-0FC33AD17D01

Q35012858-3B702702-25AF-49F8-8A71-6C1065DFB9EB

Q35012858-59FEEE06-CF4D-4753-8989-BC041A67CE53

Q35012858-6DCC1C39-7C6C-4C00-8A3F-7D2A589A470C

Q35012858-71CE6E0F-DB0A-4CD3-85D8-064410CB62D9

Q35012858-8409B432-99DE-4A29-811A-B571DB77869D

P2888

Q35012858-E3042A00-D42F-4AFC-9CA7-FC6137CB3B71

P304

Q35012858-66DD2DA8-CD22-49E6-BC90-8197A486B30F

P31

Q35012858-F0224C0A-A640-4E0B-A835-66EAEEF95A7E

P356

Q35012858-7044775E-5393-4F9E-BF33-9DF9881B8367

P433

Q35012858-54B9E43C-E2BE-4F49-9D69-A0BB9AACB4B6

P478

Q35012858-21C5BE0D-14FE-4E52-B8AC-E15E75A4E4EC

P50

Q35012858-26C64B12-6DF7-4635-860F-B1A553FBD681

P577

Q35012858-B5E31DB1-B769-4D40-80F4-0BB15397193F

P5875

Q35012858-3EDD48EB-CC4F-4742-80E1-12B18B56038D

P6179

Q35012858-C9CC30BF-FCED-456A-9588-C6E991E68A0C

P698

Q35012858-59652F8B-BCCE-43F8-815A-BEE471542A89

P921

Q35012858-646A3A06-792B-4EBC-8BFA-5BD676E073C3

Q35012858-BA677297-C3C8-4DC3-8DE9-80ABD065C7DC

P932

Q35012858-D5017739-3D7E-466B-84BC-DAB90EB2C9A8

P356

P1433

Breast Cancer Research

P1476

Evaluation of Ki-67 proliferat ...... apy for primary breast cancer.

@en

P2093

Andreas Makris

http://www.w3.org/2001/XMLSchema#string

Frances Daley

http://www.w3.org/2001/XMLSchema#string

George D Wilson

http://www.w3.org/2001/XMLSchema#string

Ifty Khan

http://www.w3.org/2001/XMLSchema#string

Paul I Richman

http://www.w3.org/2001/XMLSchema#string

Russell Burcombe

http://www.w3.org/2001/XMLSchema#string

Simone Detre

http://www.w3.org/2001/XMLSchema#string

P2860

Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer

Comparative assessment of proliferation and DNA content in breast carcinoma by image analysis and flow cytometry.

Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status.

Prognostic value of Ki-67 immunolabelling in primary operable breast cancer

Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival.

Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy.

Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi.

Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer.

Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer

Biomarkers and outcome after tamoxifen treatment in node-positive breast cancers from elderly women.

P2888

P304

R31

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/BCR1508

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

P577

2006-06-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6994422

http://www.w3.org/2001/XMLSchema#string

P6179

1019633222

http://www.w3.org/2001/XMLSchema#string

P698

16790076

http://www.w3.org/2001/XMLSchema#string

P921

apoptotic process

P932

1557736

http://www.w3.org/2001/XMLSchema#string